TrialsgrambetaRCTs are beautiful

TRITON-TIMI 38

2007

Trial to Assess Improvement in Therapeutic Outcomes

In 13,608 ACS patients undergoing planned PCI, prasugrel reduced ischaemic events but increased major bleeding relative to clopidogrel.

Result

Efficacy: CV death, non-fatal MI or non-fatal strokeHR 0.81

Below 1 favours prasugrel, above 1 favours clopidogrel.

Event rates
Absolute difference
2.2 points

The absolute difference is derived from the event rates.

Also reported: TIMI major bleed 2.4 % vs 1.8 %; fatal bleed higher with prasugrel.

Original publication
Subtopic
Antiplatelets
Design
Double-blind RCT
Relevance
Important: one of several pillars.
Source
Wiviott SD, et al. N Engl J Med. 2007;357(20):2001-2015.doi 10.1056/NEJMoa0706482

Discussion & critique

Net harm in patients > 75 y, < 60 kg, or with prior stroke/TIA. These subgroups are contraindications. Selection of P2Y12 inhibitor remains a balance of ischaemic vs bleeding risk.

Discussed in podcasts